Acrivon Therapeutics
ACRV
ACRV
47 hedge funds and large institutions have $32.6M invested in Acrivon Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Holders
47
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$960K | |
| 2 | +$194K | |
| 3 | +$160K | |
| 4 |
Two Sigma Advisers
New York
|
+$146K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$129K |
Top Sellers
| 1 | -$498K | |
| 2 | -$455K | |
| 3 | -$173K | |
| 4 |
Goldman Sachs
New York
|
-$169K |
| 5 |
Millennium Management
New York
|
-$156K |
